about
Injected nanocrystals for targeted drug deliveryGlyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin.Size-dependent penetration of nanoemulsions into epidermis and hair follicles: implications for transdermal delivery and immunization.Silymarin glyceryl monooleate/poloxamer 407 liquid crystalline matrices: physical characterization and enhanced oral bioavailability.Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media.Biotinylated liposomes as potential carriers for the oral delivery of insulin.Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile saltEnhanced effect and mechanism of water-in-oil microemulsion as an oral delivery system of hydroxysafflor yellow AEvidence does not support absorption of intact solid lipid nanoparticles via oral delivery.Enhanced dissolution and stability of lansoprazole by cyclodextrin inclusion complexation: preparation, characterization, and molecular modelingBile salt/phospholipid mixed micelle precursor pellets prepared by fluid-bed coating.Enhanced hypoglycemic effect of biotin-modified liposomes loading insulin: effect of formulation variables, intracellular trafficking, and cytotoxicityDeveloping nanocrystals for cancer treatment.Transmembrane delivery of anticancer drugs through self-assembly of cyclic peptide nanotubes.Bioimaging of nanoparticles: the crucial role of discriminating nanoparticles from free probes.In vivo fate of lipid-based nanoparticles.The in vivo fate of nanocrystals.Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems.Environment-responsive aza-BODIPY dyes quenching in water as potential probes to visualize the in vivo fate of lipid-based nanocarriers.Hyperoside nanocrystals for HBV treatment: process optimization, in vitro and in vivo evaluation.Ocular delivery of cyclosporine A based on glyceryl monooleate/poloxamer 407 liquid crystalline nanoparticles: preparation, characterization, in vitro corneal penetration and ocular irritation.Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation.The role of lipid-based nano delivery systems on oral bioavailability enhancement of fenofibrate, a BCS II drug: comparison with fast-release formulations.Effects of interior gelation on pharmacokinetics and biodistribution of liposomes encapsulating an anti-cancer drug cytarabine.Liposomes interiorly thickened with thermosensitive nanogels as novel drug delivery systems.Lecithin in mixed micelles attenuates the cytotoxicity of bile salts in Caco-2 cells.Nanoemulsion-templated shell-crosslinked nanocapsules as drug delivery systems.Influence of Particle Geometry on Gastrointestinal Transit and Absorption following Oral Administration.Piroxicam/2-hydroxypropyl-beta-cyclodextrin inclusion complex prepared by a new fluid-bed coating technique.In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing Silybum marianum extract prepared by fluid-bed coating.Size-Dependent Translocation of Nanoemulsions via Oral Delivery.Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose.Self-discriminating fluorescent hybrid nanocrystals: efficient and accurate tracking of translocation via oral delivery.Bioimaging of Intravenous Polymeric Micelles Based on Discrimination of Integral Particles Using an Environment-Responsive Probe.Epithelia transmembrane transport of orally administered ultrafine drug particles evidenced by environment sensitive fluorophores in cellular and animal studies.Overcoming or circumventing the stratum corneum barrier for efficient transcutaneous immunization.Exploiting or overcoming the dome trap for enhanced oral immunization and drug delivery.Controlling Release of Integral Lipid Nanoparticles Based on Osmotic Pump Technology.Biomimetic reassembled chylomicrons as novel association model for the prediction of lymphatic transportation of highly lipophilic drugs via the oral route.Synchronous microencapsulation of multiple components in silymarin into PLGA nanoparticles by an emulsification/solvent evaporation method.
P50
Q26752396-FEEFF1FD-3D87-41D8-9E14-9136BF2A28ADQ33573467-1E3A0F7B-3DA0-4516-851C-5A64BE9450E5Q33888745-BD42E7C5-6C8D-45C5-91B5-BE4534B89499Q34030782-23EF503B-84EE-4F93-B097-C44CC3602F04Q34454557-E7EEAD2E-C08D-4BB2-8EA0-F9F32DA548F0Q34869982-B435698F-27CF-4360-A9AF-9ADFFE850A29Q35071614-B11DF2DF-225C-4224-A390-9901FB44E85BQ35071621-3B27E79C-5A7F-4D7A-82C5-AFA99A4EEDCFQ35883589-84785073-5090-48CB-A586-B945B2D2BED2Q36442107-EB652299-72C8-49D9-A995-FA7EC06DF453Q36805049-B662C9C7-49E8-4A79-8B3B-DE4644222632Q37718748-56599333-FF7E-41CD-B23C-4FF58103C738Q38570503-AF853CD8-75FC-4F79-A33B-53C55F5F8E13Q38787285-01B856DA-3FDD-4766-9738-CE049DE554E5Q38808416-DE979980-8754-4034-AB9E-1216BAE3D690Q38974104-BD0BF0BF-CF03-4D7D-B0C3-9018E9B46813Q39088854-7B763CAD-52D3-409B-962A-B18D130326F3Q39574444-70C8823B-4C0A-438B-BBE1-51367B4F7949Q40723013-FC969C1D-862F-453D-A5DB-2D42F7047B0EQ40824411-A79FFBD0-C501-449B-880C-5C579D023DE0Q41612480-5EBD5B3A-23B2-419A-9F91-E66C0B8BC7F7Q41843445-DB718E93-723B-49AD-833E-F36881D4AA11Q41889403-9522D7D6-0DEA-4FF9-9A6A-0099E9CFA3AAQ42747972-4D49479A-54DE-493E-B338-A5FBF0E219ABQ43504367-46C75856-9598-442B-A28E-3199FD315844Q45064205-03D7CBB7-99C3-4642-B1DA-B1A4635BCE5FQ45385712-6A8FC321-7E17-4C8B-AAE1-EFC5EA3573A3Q46398389-25672FCD-3938-4966-AFFD-0E802D2DE60BQ46548646-DE901557-5159-449D-B935-36D812F02066Q46778816-7D6ACF27-EA27-4B9F-9D92-FB8C61A583AFQ47206101-C1F21E57-4077-4933-9551-7B72C37118F2Q47324533-97CB0307-BB5A-4657-9507-03A5D6C714B8Q47760779-DA94096E-0191-42A4-A425-F646D2CAED94Q48470680-B6D9E383-5F2E-48BD-B2D7-C2052EF9AA08Q49358487-2EB5ABA1-CCFC-4656-8EB6-FC57394C83C7Q49496327-EF1354F4-74DB-430C-9DA8-9FD475C65AF0Q49897080-2E4965EE-C8E4-44A5-AB85-43CB5C3DD359Q50854702-28E11BA5-22A4-4A26-ADBA-611A69DEC1DAQ50959041-25BB5232-53F5-4E94-BF6C-AD2F9E304607Q50977639-618AD424-41B6-4662-96CD-31B9A27DC1F1
P50
description
researcher ORCID: 0000-0002-9655-7510
@en
name
Yi Lu
@ast
Yi Lu
@en
Yi Lu
@es
Yi Lu
@nl
Yi Lu
@sl
type
label
Yi Lu
@ast
Yi Lu
@en
Yi Lu
@es
Yi Lu
@nl
Yi Lu
@sl
prefLabel
Yi Lu
@ast
Yi Lu
@en
Yi Lu
@es
Yi Lu
@nl
Yi Lu
@sl
P1053
E-4461-2015
P106
P31
P3829
P3835
P496
0000-0002-9655-7510